FDA Panel Recommends T-Cell Lymphoma Drug

An FDA panel of cancer experts has voted 10-4 in favor of FDA approval for pralatrexate, an experimental cancer drug for T-cell lymphomas developed by Allos Therapeutics.

Currently there are no FDA-approved drug treatments for T-cell lymphoma; pralatrexate would be the first. It has shown to be effective in cases of refractory or recurring T-cell lymphoma.

The FDA does not have to take the panel's recommendation. Typically, though, it does. In this case they'll make their decision by September 24.

If approved, pralatrexate will be a boon for Allos Therapeutics. If approved, expect it to be costly—in the extreme.

LymphomaInfo Social